A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models
These findings highlight TAVO412 as a promising therapeutic agent with multiple mechanisms of action and strong potential for synergistic combinations in NSCLC treatment.
Authors
- Hao Jiang (ORCID: https://orcid.org/0000-0002-1234-624X)
- Meixia Fu
- Guangmao Mu
- Ping Sun (ORCID: https://orcid.org/0000-0002-0998-0514)
- Peng Chen
- Mark L. Chiu (ORCID: https://orcid.org/0000-0001-6300-404X)
- Simin Wu
- Yuqiang Xu
- Zhengxia Zha (ORCID: https://orcid.org/0000-0002-9148-333X)
- Fulai Zhou (ORCID: https://orcid.org/0000-0002-3840-6757)
- Sheng Huang (ORCID: https://orcid.org/0009-0001-9298-7548)
- Ying Jin (ORCID: https://orcid.org/0000-0001-5681-9339)
- Chao Han (ORCID: https://orcid.org/0009-0002-4581-545X)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-16
- DOI
- https://doi.org/10.3389/fonc.2025.1533059
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 7.59